OnKure Therapeutics, Inc. (OKUR)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 12,613 | |||
| General and administrative | 3,711 | |||
| Total operating expenses | 16,324 | |||
| Loss from operations | -16,324 | |||
| Interest income | 934 | |||
| Total other income and (expense) | 934 | |||
| Net loss and comprehensive loss | -15,390 | |||
| Earnings per share, basic, total | -1.14 | |||
| Net loss per share attributable to common stockholders, diluted | -1.14 | |||
| Weighted average number of shares outstanding, basic, total | 13,509,080 | |||
| Weighted average number of shares outstanding, diluted | 13,509,080 | |||